HER2 Vaccine May Reduce Breast Cancer Recurrence

According to results recently presented at the 2006 annual San Antonio Breast Cancer Symposium (SABCS), an experimental HER2 vaccine may reduce the risk of cancer recurrence in some women with high-risk early breast cancer. Although cure rates remain high for patients with early breast cancer, particularly women with node-negative breast cancer, some of these women will experience a cancer recurrence and may ultimately succumb to their disease. Therefore, a reduction in the risk of recurrence among high-risk women is warranted. HER2 is a protein that is overexpressed in twenty to thirty percent of breast cancers. Using a part of the HER2 protein (the E75 peptide), researchers have developed an experimental anticancer vaccine. --Click the title of this post to read the full article from its source--